Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | presenilin enhancer 2 | 0.0227 | 0.0474 | 0.0368 |
Loa Loa (eye worm) | gamma-secretase subunit aph-1 | 0.3085 | 1 | 1 |
Entamoeba histolytica | presenilin 1 peptidase, putative | 0.0242 | 0.0524 | 0.5 |
Trypanosoma cruzi | Aph-1 protein, putative | 0.1202 | 0.3724 | 1 |
Echinococcus granulosus | gamma secretase subunit aph 1 | 0.3085 | 1 | 1 |
Trichomonas vaginalis | Clan AD, family A22, presenilin-like aspartic peptidase | 0.0242 | 0.0524 | 1 |
Leishmania major | presenilin-like aspartic peptidase, putative,presenilin-like aspartic peptidase, clan AD, family A22A, putative | 0.0242 | 0.0524 | 0.5 |
Echinococcus granulosus | presenilin | 0.0242 | 0.0524 | 0.0418 |
Trichomonas vaginalis | Clan AD, family A22, presenilin-like aspartic peptidase | 0.0242 | 0.0524 | 1 |
Loa Loa (eye worm) | gamma-secretase subunit pen-2 | 0.0227 | 0.0474 | 0.0474 |
Brugia malayi | Presenilin family protein | 0.0242 | 0.0524 | 0.0524 |
Trypanosoma brucei | Aph-1 protein, putative | 0.1202 | 0.3724 | 1 |
Echinococcus multilocularis | presenilin enhancer 2 | 0.0227 | 0.0474 | 0.0368 |
Trypanosoma cruzi | Aph-1 protein, putative | 0.1202 | 0.3724 | 1 |
Brugia malayi | hypothetical protein | 0.0118 | 0.0111 | 0.0111 |
Schistosoma mansoni | subfamily A22A unassigned peptidase (A22 family) | 0.0242 | 0.0524 | 0.0418 |
Trichomonas vaginalis | Clan AD, family A22, presenilin-like aspartic peptidase | 0.0242 | 0.0524 | 1 |
Brugia malayi | gamma-secretase subunit pen-2 | 0.0227 | 0.0474 | 0.0474 |
Echinococcus multilocularis | gamma secretase subunit aph 1 | 0.3085 | 1 | 1 |
Echinococcus multilocularis | presenilin | 0.0242 | 0.0524 | 0.0418 |
Toxoplasma gondii | hypothetical protein | 0.0085 | 0 | 0.5 |
Schistosoma mansoni | gamma-secretase subunit aph-1 | 0.3085 | 1 | 1 |
Brugia malayi | hypothetical protein | 0.0118 | 0.0111 | 0.0111 |
Loa Loa (eye worm) | hypothetical protein | 0.0118 | 0.0111 | 0.0111 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.